Cholangiocarcinomas Completed Phase 1 Trials for Erlotinib (DB00530)

Also known as: Cholangiocarcinoma / Cholangiocarcinoma NOS / Cholangiocarcinoma of biliary tract

IndicationStatusPhase
DBCOND0051818 (Cholangiocarcinomas)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00955149Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC)Prevention